JPRN-jRCT2061200051进行中（未招募）3 期
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ON-DEMAND TACE COMBINED WITH ATEZOLIZUMAB PLUS BEVACIZUMAB (ATEZO/BEV) OR ON-DEMAND TACE ALONE IN PATIENTS WITH UNTREATED HEPATOCELLULAR CARCINOMA
idan Bai0 个研究点目标入组 342 人开始时间: 2021年2月2日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 342
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •onfirmed diagnosis of HCC by histology/ cytology or clinical criteria
- •- Eligible for TACE treatment
- •- No prior systemic therapy for HCC, especially immunotherapy
- •- No prior locoregional therapy to the target lesion(s)
- •- At least one measurable untreated lesion
- •- ECOG Performance Status of 0-1
- •- Child-Pugh class A
排除标准
- •Evidence of Vp3/4 and hepatic vein tumor thrombus (HVTT)
- •Evidence of extrahepatic spread (EHS)
- •Being a candidate for curative treatments
- •Any condition representing a contraindication to TACE as determined by the investigators
- •Active or history of autoimmune disease or immune deficiency
- •Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding
- •A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
- •Evidence of bleeding diathesis or significant coagulopathy
研究者
相似试验
招募中
不适用
A PHASE III STUDY OF PEMBROLIZUMAB VS. PHYSICIANS’ CHOICE OF DOCETAXEL,PACLITAXEL OR IRINOTECAN IN 2L SUBJECTS WITH ADVANCED/METASTATICADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUSPER-068-15MERCK SHARP & DOHME PERU S.R.L.,2
招募中
不适用
A RANDOMIZED OPEN-LABEL PHASE III STUDY OF SINGLE AGENT PEMBROLIZUMAB VERSUS SINGLEAGENT CHEMOTHERAPY PER PHYSICIAN’S CHOICE FOR METASTATIC TRIPLE NEGATIVE BREAST CANCER(MTNBC) – (KEYNOTE-119)-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-066-15MERCK SHARP & DOHME PERU S.R.L.,8
已完成
不适用
PHASE III RANDOMIZED, OPEN LABEL STUDY OF SINGLE AGENT OFATUMUMAB VS. SINGLE AGENT RITUXIMAB IN FOLLICULAR LYMPHOMA RELAPSED AFTER RITUXIMAB-CONTAINING THERAPY-C82 Follicular lymphomaC82Follicular lymphomaPER-072-10OVARTIS BIOSCIENSES PERU S.A.,8
招募中
不适用
A PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF DOLUTEGRAVIR OR EFAVIRENZ EACH ADMINISTERED WITH TWO NRTIS IN HIV-1-INFECTED ANTIRETROVIRAL THERAPY-NAÏVE ADULTS STARTING TREATMENT FOR RIFAMPICIN-SENSITIVE TUBERCULOSISPER-069-14ViiV Healthcare UK Limited,14
进行中（未招募）
1 期
A STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS STANDARD OF CARE IN PATIENTS WITH LUNG CANCERon-Small Cell Lung CancerEUCTR2016-004407-31-BGRegeneron Pharmaceuticals, Inc.700